Toth Financial Advisory Corp Has $660,000 Stock Position in Insulet Corporation $PODD

Key Points

• Toth Financial Advisory Corp significantly increased its stake in Insulet Corporation by 105,000% during Q2, now holding 2,102 shares valued at $660,000.
• Insulet's stock price recently opened at $330.84 and reported quarterly earnings of $1.17 EPS, surpassing analyst expectations.
• Analysts have raised price targets for Insulet with JPMorgan setting a new target of $415.00 and maintaining an "overweight" rating.

Toth Financial Advisory Corp increased its position in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 105,000.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,102 shares of the medical instruments supplier's stock after buying an additional 2,100 shares during the quarter. Toth Financial Advisory Corp's holdings in Insulet were worth $660,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Larson Financial Group LLC increased its holdings in shares of Insulet by 426.3% in the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock worth $26,000 after buying an additional 81 shares during the period. Zions Bancorporation National Association UT purchased a new stake in shares of Insulet during the 1st quarter valued at about $26,000. SouthState Corp grew its stake in Insulet by 253.3% in the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock worth $28,000 after acquiring an additional 76 shares in the last quarter. Kozak & Associates Inc. acquired a new stake in Insulet in the second quarter valued at approximately $32,000. Finally, Ramirez Asset Management Inc. acquired a new stake in shares of Insulet in the first quarter valued at about $53,000.

Analyst Ratings Changes

PODD has been the subject of a number of recent research reports. JPMorgan Chase & Co. increased their price target on shares of Insulet from $340.00 to $415.00 and gave the stock an "overweight" rating in a research note on Friday, September 12th. Morgan Stanley reaffirmed an "overweight" rating on shares of Insulet in a research note on Thursday, August 7th. Citigroup reaffirmed a "buy" rating on shares of Insulet in a research report on Tuesday, July 8th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Insulet in a research report on Thursday, August 7th. Finally, Raymond James Financial reiterated an "outperform" rating and issued a $360.00 price objective (up from $328.00) on shares of Insulet in a research report on Tuesday, May 27th. Sixteen investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, Insulet has an average rating of "Moderate Buy" and an average price target of $343.06.

Insulet Price Performance

Insulet stock traded up $4.28 during midday trading on Monday, hitting $335.12. 431,486 shares of the company's stock were exchanged, compared to its average volume of 593,672. The company has a market cap of $23.59 billion, a P/E ratio of 101.86, a PEG ratio of 2.75 and a beta of 1.36. Insulet Corporation has a 52-week low of $225.37 and a 52-week high of $353.50. The stock has a 50-day moving average price of $316.00 and a two-hundred day moving average price of $295.09. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping analysts' consensus estimates of $0.92 by $0.25. The company had revenue of $649.10 million for the quarter, compared to analysts' expectations of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.Insulet's revenue for the quarter was up 32.9% compared to the same quarter last year. During the same period last year, the firm earned $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities research analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current year.

Insider Buying and Selling at Insulet

In other news, SVP Laetitia Cousin sold 797 shares of the stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares of the company's stock, valued at $1,356,870.90. This represents a 17.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Prem Singh sold 687 shares of the firm's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president owned 3,456 shares of the company's stock, valued at $1,200,925.44. This represents a 16.58% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by corporate insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.